These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26769867)

  • 41. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
    Carome M; Wolfe S
    JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessment and approval of medical devices used in diagnostic imaging in the United States.
    Johnson GC
    Isr J Med Sci; 1986; 22(7-8):505-18. PubMed ID: 3536797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fast high performance liquid chromatography in PET quality control and metabolite analysis.
    Passchier J
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):411-6. PubMed ID: 19834451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG positron emission tomography in lymphoma.
    Tecnologica MAP Suppl; 2000 Jan; ():9-10. PubMed ID: 10848116
    [No Abstract]   [Full Text] [Related]  

  • 45. FDG positron emission tomography in colorectal cancer.
    Tecnologica MAP Suppl; 2000 Jan; ():6-8. PubMed ID: 10848115
    [No Abstract]   [Full Text] [Related]  

  • 46. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA involvement in PET: help or hindrance? Part II.
    Kotz D
    J Nucl Med; 1997 Feb; 38(2):9N-11N, 19N. PubMed ID: 9025726
    [No Abstract]   [Full Text] [Related]  

  • 48. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulatory Requirements for PET Drug Production.
    Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
    J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare coverage of new PET radiopharmaceuticals.
    Hillman BJ; Frank RA; Abraham BC
    J Nucl Med; 2013 Sep; 54(9):1675-9. PubMed ID: 23907756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nuclear medicine wins decision in FDA PET case.
    Nichols D
    J Nucl Med; 1997 Dec; 38(12):23N. PubMed ID: 9430453
    [No Abstract]   [Full Text] [Related]  

  • 53. Enantiopure bifunctional chelators for copper radiopharmaceuticals--does chirality matter in radiotracer design?
    Singh AN; Dakanali M; Hao G; Ramezani S; Kumar A; Sun X
    Eur J Med Chem; 2014 Jun; 80():308-15. PubMed ID: 24793881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Federal regulations and reimbursement for PET.
    Keppler JS
    J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory and reimbursement challenges for molecular imaging.
    Hoffman JM; Gambhir SS; Kelloff GJ
    Radiology; 2007 Dec; 245(3):645-60. PubMed ID: 18024447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Target-specific delivery of peptide-based probes for PET imaging.
    Chen K; Conti PS
    Adv Drug Deliv Rev; 2010 Aug; 62(11):1005-22. PubMed ID: 20851156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GE β-amyloid agent approved.
    J Nucl Med; 2013 Dec; 54(12):10N. PubMed ID: 24297736
    [No Abstract]   [Full Text] [Related]  

  • 58. Small-animal positron emission tomography as a tool for neuropharmacology.
    Lancelot S; Zimmer L
    Trends Pharmacol Sci; 2010 Sep; 31(9):411-7. PubMed ID: 20599282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.
    Bernard-Gauthier V; Aliaga A; Aliaga A; Boudjemeline M; Hopewell R; Kostikov A; Rosa-Neto P; Thiel A; Schirrmacher R
    ACS Chem Neurosci; 2015 Feb; 6(2):260-76. PubMed ID: 25350780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical decision rules in radiology.
    Reed MH
    Acad Radiol; 2006 May; 13(5):562-5. PubMed ID: 16627196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.